IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application)	PATENT APPLICATION
Inventor(s): Charles Semba)	
)	Art Unit: 1651
Application No.: 10/697,142)	
Filed: October 30, 2003)	Examiner: Underdahl, Thane
Title Plasminogen activator variant formulations)	

INFORMATION DISCLOSURE STATEMENT UNDER 37 C.F.R. §1.97

Mail Stop ____ Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

Sir:

Listed below or on an attached Form PTO-1449 is information known to applicant(s). A copy of each listed publication and U.S. and foreign patent, except for pending U.S. applications, is being submitted herewith, along with a concise explanation of information in a foreign language, if any, pursuant to 37 C.F.R. \$1.97-1.98.

Applicants respectfully request that the listed information be considered by the Examiner and be made of record in the above-identified application. If form PTO-1449 is enclosed, the Examiner is requested to initial and return it in accordance with MPEP §609.

This statement is not intended to represent that a search has been made or that the information cited in the statement is, or is considered to be, material to patentability as defined in §1.56.

	This statement qualifies under 37 C.F.R. §1.97, subsection (b) because (check all that apply):			subsection (b) because (check all that apply):		
		(1)	It is being filed within 3 months continued prosecution application OR	of the application filing date and is other than a on under § 1.53(d)		
		(2)	1t is being filed within 3 months	of entry of a national stage		
		(3)		date of the first Office Action on the merits		
		(4)		ng of a first Office Action after the filing of a request r \S 1.114.		
\boxtimes	37 C.F.R. §1.97(c). If this statement is being filed after the latest of: (1) three months beyond the filing date of a national application; (2) three months beyond the date of entry of the national stage a set forth in §1.491 in an international application; or (3) the mailing date of a first Office action on the merits, but before the mailing date of the earlier of a final office action under §1.113 or a notice of allowance under §1.311, then:					
		a certification as specified in §1.97(e) is provided below; or				
		a fee o payme	f \$180.00 as set forth in \$1.17(p) nt of other papers filed together v	is authorized below, enclosed, or included with the with this statement.		
	37 C.F.R. §1.97(d). If this statement is being filed after the mailing date of the earlier of a final caction under §1.113 or a notice of allowance under §1.311, but before payment of the issue fee, the			ed after the mailing date of the earlier of a final office der §1.311, but before payment of the issue fee, then:		
	A.	a certif	ication as specified in §1.97(e) is	completed below; and		
	B.	a petition under 37 C.F.R. $\S 1.97(d)$ requesting consideration of this statement is submitted herewith; and				
	C.	a fee of \$130.00 as set forth in $\S1.17(i)(1)$ is authorized below, enclosed, or included with the payment of other papers filed together with this statement.				
	Fee Authorization. The Commissioner is hereby authorized to charge the above-referenced fees or \$0.00 and charge any additional fees or credit any overpayment associated with this communication Deposit Account No. 50-4634 (Docket No. 123851-181802).					
				Respectfully submitted, GOODWIN PROCTER LLP		
Dated:	-	Novem	ber 6, 2008	By: Jeffrey & Talkington, Rev. No. 58,381		
135 Co Menlo (650) 7		vealth D A 94025)		V \)		